FDA approves ocrelizumab in RRMS, PPMS

 

The U.S. Food and Drug Administration has approved ocrelizumab (Ocrevus) for the treatment of adult patients with relapsing forms of multiple sclerosis, and for primary-progressive MS. Ocrelizumab is a humanized monoclonal antibody that targets CD20+ B cells. It is the first disease-modifying therapy to be approved for PPMS. The FDA had given ocrelizumab breakthrough therapy and fast track designations, and granted it a priority review.

It takes 30 seconds

TOPICS:
Recommend to a Colleague

Related Posts

Go back to home page